Institution · Accumed Research Associates

Most cited papers from Accumed Research Associates

Accumed Research Associates

What are the most cited papers from Accumed Research Associates?

The most cited paper from Accumed Research Associates is "A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer" (Channing Judith Paller, Xiquan Ye, Paulina Woźniak et al., 2012), with 186 citations. Next come "PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study" (148) and "A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients" (96).

Published FieldAccess

Showing 17 of 17 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer Channing Judith Paller, Xiquan Ye, Paulina Woźniak et al. · Prostate Cancer and Prostatic Diseases Open access	12 Jun 2012	186
2	PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study MARC C. GITTELMAN, Bernard Hertzman, James L. Bailen et al. · The Journal of Urology	15 Feb 2013	148
3	A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients Edward M. Messing, Jason Gee, Daniel R. Saltzstein et al. · Cancer Prevention Research Open access	Feb 2012	96
4	The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia Steven A. Kaplan, Jared L. Moss, Sheldon J. Freedman et al. · The Journal of Urology Open access	9 Aug 2023	47
5	External electrical stimulation compared with intravaginal electrical stimulation for the treatment of stress urinary incontinence in women: A randomized controlled noninferiority trial Roger Roman Dmochowski, Catherine M. Lynch, Mitchell D. Efros et al. · Neurourology and Urodynamics	3 Jul 2019	43
6	A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of OnabotulinumtoxinA 200 U to Treat Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia Kevin T. McVary, Claus G. Roehrborn, Emmanuel Jean Chartier-Kastler et al. · The Journal of Urology	6 Feb 2014	43
7	Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor overactivity from two double‐blind, imbalanced, placebo‐controlled randomized phase 1 trials Eric S. Rovner, Toby C. Chai, Sharon Jacobs et al. · Neurourology and Urodynamics Open access	16 Jan 2020	35
8	Effect of Tadalafil Once Daily on Prostate Blood Flow and Perfusion in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Randomized, Double-blind, Multicenter, Placebo-controlled Trial Germar‐Michael Pinggera, Ferdinand Frauscher, Darius A. Paduch et al. · Urology	16 Jun 2014	26
9	Efficacy and Safety of a New Topical Testosterone Replacement Gel Therapy for the Treatment of Male Hypogonadism Glenn R. Cunningham, Laurence H Belkoff, Gerald B Brock et al. · Endocrine Practice	22 Feb 2017	17
10	Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification Yair Lotan, Jay D. Raman, Badrinath R. Konety et al. · The Journal of Urology Open access	30 Dec 2022	16
11	Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement Neal D. Shore, Ronald F. Tutrone Jr., Mitchell D. Efros et al. · World Journal of Urology Open access	29 Jan 2018	16
12	Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial David F. Penson, Andrew J. Armstrong, Raoul S. Concepcion et al. · Prostate Cancer and Prostatic Diseases Open access	7 Oct 2021	10
13	The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies Mitchell D. Efros, Dario Carrara, Anders Neijber · Andrologia	24 Nov 2015	9
14	Lessons Learned From a Direct Data Entry Phase 2 Clinical Trial Under a US Investigational New Drug Application Jules T. Mitchel, Judith M. Schloss Markowitz, Yin Hua et al. · Drug Information Journal	Jul 2012	3
15	Ambulatory Blood Pressure Parameters Among Men With Hypogonadism Treated With Testosterone Transdermal Therapy Mitchell D. Efros, Jed C. Kaminetsky, Neil D. Sherman et al. · Endocrine Practice Open access	12 Jun 2024	2
16	Single‐arm study of testosterone gel replacement therapy and ambulatory blood pressure outcomes in men with hypogonadism Michael A. Weber, Shamaila Aslam, Mitchell D. Efros et al. · Andrology	9 Oct 2024	1
17	12-MONTH OUTCOMES FROM A RANDOMIZED, DOUBLE-BLIND, SHAM CONTROLLED STUDY EVALUATING A NOVEL DRUG COATED BALLOON FOR THE TREATMENT OF BPH Dean Elterman, Steven A. Kaplan, Jonathan G. Moss et al. · Continence Open access	12 Jul 2023	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.